Vangveravong Suwanna, McElveen Elizabeth, Taylor Michelle, Xu Jinbin, Tu Zhude, Luedtke Robert R, Mach Robert H
Division of Radiological Sciences, Washington University School of Medicine, Mallinckrodt Institute of Radiology, St. Louis, MO 63110, USA.
Bioorg Med Chem. 2006 Feb 1;14(3):815-25. doi: 10.1016/j.bmc.2005.09.008. Epub 2005 Nov 8.
A series of indole compounds have been prepared and evaluated for affinity at D2-like dopamine receptors using stably transfected HEK cells expressing human D2, D3, or D4 dopamine receptors. These compounds share structural elements with the classical D2-like dopamine receptor antagonists, haloperidol, N-methylspiperone, and benperidol. The compounds that share structural elements with N-methylspiperone and benperidol bind non-selectively to the D2 and D3 dopamine receptor subtypes. However, several of the compounds structurally similar to haloperidol were found to (a) bind to the human D2 receptor subtype with nanomolar affinity, (b) be 10- to 100-fold selective for the human D2 receptor compared to the human D3 receptor, and (c) bind with low affinity to the human D4 dopamine receptor subtype. Binding at sigma (sigma) receptor subtypes, sigma1 and sigma2, were also examined and it was found that the position of the methoxy group on the indole was pivotal in both (a) D2 versus D3 receptor selectivity and (b) affinity at sigma1 receptors. Adenylyl cyclase studies indicate that our indole compounds with the greatest D2 receptor selectivity are neutral antagonists at human D2 dopamine receptor subtypes. With stably transfected HEK cells expressing human D2 (hD2-HEK), these compounds (a) have no intrinsic activity and (b) attenuated quinpirole inhibition of adenylyl cyclase. The D2 receptor selective compounds that have been identified represent unique pharmacological tools that have potential for use in studies on the relative contribution of the D2 dopamine receptor subtypes in physiological and behavioral situations where D2-like dopaminergic receptor involvement is indicated.
已经制备了一系列吲哚化合物,并使用稳定转染表达人D2、D3或D4多巴胺受体的HEK细胞,评估了它们对D2样多巴胺受体的亲和力。这些化合物与经典的D2样多巴胺受体拮抗剂氟哌啶醇、N-甲基螺哌隆和苯哌利多具有共同的结构元素。与N-甲基螺哌隆和苯哌利多具有共同结构元素的化合物非选择性地结合D2和D3多巴胺受体亚型。然而,发现几种结构与氟哌啶醇相似的化合物:(a) 以纳摩尔亲和力与人D2受体亚型结合;(b) 与人D3受体相比,对人D2受体具有10至100倍的选择性;(c) 与人类D4多巴胺受体亚型的结合亲和力较低。还研究了它们与σ(sigma)受体亚型σ1和σ2的结合情况,发现吲哚上甲氧基的位置在(a) D2与D3受体选择性以及(b) 与σ1受体的亲和力方面都起着关键作用。腺苷酸环化酶研究表明,我们具有最高D2受体选择性的吲哚化合物是人类D2多巴胺受体亚型的中性拮抗剂。对于稳定转染表达人D2(hD2-HEK)的HEK细胞,这些化合物:(a) 没有内在活性;(b) 减弱了喹吡罗对腺苷酸环化酶的抑制作用。已鉴定出的D2受体选择性化合物代表了独特的药理学工具,有可能用于研究D2样多巴胺能受体参与的生理和行为情况下D2多巴胺受体亚型的相对贡献。